Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation.

Cristina Guiotto,Angelo Italia,Alessandro Lavagna,Caterina Rigazio,Maurizio Cosimato,Elena Ercole,Marco Mendolaro,Rodolfo Rocca,Marco Daperno

Digestive and Liver Disease（2019）

引用 5|浏览54

暂无评分

摘要

This study confirms that switching from infliximab originator to a first biosimilar is safe and effective. Patients at highest risk of losing treatment efficacy are those with active disease, irrespective of the therapeutic switch.

查看译文

关键词

Anti-TNF,Crohn’s disease,CT-P13,Inflammatory bowel disease,Ulcerative colitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要